Zobrazeno 1 - 4
of 4
pro vyhledávání: '"H. H. Gillenwater"'
Autor:
Joseph Treat, Kendrith M. Rowland, H. H. Gillenwater, Robert L. Comis, Robert B. Catalano, Donna M. Marinucci, Mark A. Socinski, René Gonin, Chandra P. Belani, Rafat Ansari, Coleman K. Obasaju, Martin J. Edelman
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 21(3)
Background Paclitaxel–carboplatin is used as the standard regimen for patients with advanced or metastatic non-small-cell lung cancer (NSCLC). This trial was designed to compare gemcitabine + carboplatin or gemcitabine + paclitaxel to the standard
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b1400b1c86c05b6b5239b4697b80455
https://pubmed.ncbi.nlm.nih.gov/19833819
https://pubmed.ncbi.nlm.nih.gov/19833819
Autor:
Gary M. Strauss, David H. Harpole, David J. Sugarbaker, Stephen L. Graziano, David W. Johnstone, Michael A. Maddaus, Xiaofei Wang, E. E. Vokes, Robert A. Kratzke, J. Crawford, Richard L. Schilsky, H. H. Gillenwater, Lin Gu, Elizabeth Johnson, Mark R. Green
Publikováno v:
Journal of Clinical Oncology. 29:7015-7015
7015 Background: The value of AC in stage IB NSCLC remains controversial. In 2004, preliminary results of CALGB 9633 demonstrated a statistically significant overall survival (OS) advantage for pts randomized to adjuvant paclitaxel and carboplatin in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::319bdac79c9ecd4a0095d55d90391fda
https://doi.org/10.1200/jco.2011.29.15_suppl.7015
https://doi.org/10.1200/jco.2011.29.15_suppl.7015
Autor:
Zhu X; Department of Medicine, Northwest Lipid Research Clinic, University of Washington, Seattle 98104, USA., Bonet B, Gillenwater H, Knopp RH
Publikováno v:
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) [Proc Soc Exp Biol Med] 1999 Dec; Vol. 222 (3), pp. 214-21.
Autor:
Socinski MA; Multidisciplinary Thoracic Oncology Program, University of North Carolina at Chapel Hill, USA., Steagall A, Gillenwater H
Publikováno v:
Cancer investigation [Cancer Invest] 1999; Vol. 17 (3), pp. 181-8.